Vincenzo Corbo

List of Publications by Year
in descending order

219 papers	35,392 citations	8172 76 h-index	3576 181 g-index
227 all docs	227 docs citations	227 times ranked	39509 citing authors

#	Article	IF	Citations
1	Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 2012, 12, 253-268.	10.6	3,002
2	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	13.7	2,700
3	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications, 2016, 7, 12150.	5.8	2,076
4	PD-L1 is a novel direct target of HIF-1Î±, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. Journal of Experimental Medicine, 2014, 211, 781-790.	4.2	1,601
5	Regulation of immune responses by L-arginine metabolism. Nature Reviews Immunology, 2005, 5, 641-654.	10.6	1,516
6	Altered macrophage differentiation and immune dysfunction in tumor development. Journal of Clinical Investigation, 2007, 117, 1155-1166.	3.9	1,031
7	Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPÎ² Transcription Factor. Immunity, 2010, 32, 790-802.	6.6	782
8	Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. Journal of Clinical Investigation, 2006, 116, 2777-2790.	3.9	723
9	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, 2012, 18, 1254-1261.	15.2	721
10	The Spleen in Local and Systemic Regulation of Immunity. Immunity, 2013, 39, 806-818.	6.6	707
11	Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology, 2006, 16, 53-65.	4.3	690
12	Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine, 2006, 203, 2691-2702.	4.2	683
13	The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Research, 2007, 67, 425-425.	0.4	649
14	Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism. Journal of Immunology, 2002, 168, 689-695.	0.4	585
15	Myeloid-derived suppressor cell heterogeneity and subset definition. Current Opinion in Immunology, 2010, 22, 238-244.	2.4	579
16	Tumorâ€induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews, 2008, 222, 162-179.	2.8	569
17	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. Journal of Experimental Medicine, 2011, 208, 1949-1962.	4.2	547
18	L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends in Immunology, 2003, 24, 301-305.	2.9	508

#	Article	IF	Citations
19	Hierarchy of immunosuppressive strength among myeloidâ€derived suppressor cell subsets is determined by GMâ€CSF. European Journal of Immunology, 2010, 40, 22-35.	1.6	479
20	High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells. Cancer Research, 2004, 64, 6337-6343.	0.4	477
21	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood, 2000, 96, 3838-3846.	0.6	474
22	IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice. Journal of Immunology, 2003, 170, 270-278.	0.4	445
23	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. Journal of Clinical Investigation, 2015, 125, 3365-3376.	3.9	443
24	Immune suppressive mechanisms in the tumor microenvironment. Current Opinion in Immunology, 2016, 39, 1-6.	2.4	407
25	Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities. Medicinal Research Reviews, 2007, 27, 317-352.	5.0	402
26	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	1.1	390
27	Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. Journal of Experimental Medicine, 2005, 201, 1257-1268.	4.2	352
28	Myeloidâ€derived suppressor cell heterogeneity in human cancers. Annals of the New York Academy of Sciences, 2014, 1319, 47-65.	1.8	349
29	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011, 118, 2254-2265.	0.6	328
30	Derangement of immune responses by myeloid suppressor cells. Cancer Immunology, Immunotherapy, 2004, 53, 64-72.	2.0	321
31	IL4RÎ±+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients. Journal of Immunology, 2009, 182, 6562-6568.	0.4	287
32	Control of immune response by amino acid metabolism. Immunological Reviews, 2010, 236, 243-264.	2.8	273
33	Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4185-4190.	3.3	271
34	A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. Immunity, 2017, 46, 233-244.	6.6	241
35	Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells. Journal of Immunotherapy, 2001, 24, 431-446.	1.2	234
36	Baricitinib restrains the immune dysregulation in patients with severe COVID-19. Journal of Clinical Investigation, 2020, 130, 6409-6416.	3.9	213

#	Article	IF	Citations
37	Part I: Vaccines for solid tumours. Lancet Oncology, The, 2004, 5, 681-689.	5.1	202
38	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood, 2011, 117, 7053-7062.	0.6	199
39	Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen. Cell Reports, 2012, 2, 628-639.	2.9	196
40	Myeloid-derived Suppressor Cells in Cancer Patients. Journal of Immunotherapy, 2012, 35, 107-115.	1.2	195
41	Therapeutic targeting of myeloid-derived suppressor cells. Current Opinion in Pharmacology, 2009, 9, 470-481.	1.7	188
42	Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood, 2006, 107, 2846-2854.	0.6	183
43	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
44	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunology, Immunotherapy, 2016, 65, 161-169.	2.0	175
45	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	0.6	174
46	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	5.7	160
47	Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells. Cancer Research, 2005, 65, 3920-3927.	0.4	157
48	Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3183-3188.	3.3	146
49	Immortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes. Journal of Immunology, 2000, 165, 6723-6730.	0.4	146
50	DC-SIGN+ Macrophages Control the Induction of Transplantation Tolerance. Immunity, 2015, 42, 1143-1158.	6.6	144
51	Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2975-2989.	1.1	144
52	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell, 2016, 30, 377-390.	7.7	141
53	MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocrine-Related Cancer, 2010, 17, 771-783.	1.6	135
54	Role of arginine metabolism in immunity and immunopathology. Immunobiology, 2008, 212, 795-812.	0.8	133

#	Article	IF	Citations
55	Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer. Nature Medicine, 2015, 21, 117-119.	15.2	131
56	miR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis. Immunity, 2013, 38, 1236-1249.	6.6	127
57	Myeloidâ€derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions. European Journal of Immunology, 2009, 39, 2670-2672.	1.6	126
58	Monocytes in the Tumor Microenvironment. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 93-122.	9.6	126
59	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
60	Myeloid-Derived Suppressor Activity Is Mediated by Monocytic Lineages Maintained by Continuous Inhibition of Extrinsic and Intrinsic Death Pathways. Immunity, 2014, 41, 947-959.	6.6	121
61	Complexity and challenges in defining myeloid-derived suppressor cells. , 2015, 88, 77-91.		119
62	Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials, 2016, 96, 47-62.	5.7	118
63	Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Trends in Immunology, 1990, 11, 274-277.	7.5	116
64	Small Noncoding RNAs in Cells Transformed by Human T-Cell Leukemia Virus Type 1: a Role for a tRNA Fragment as a Primer for Reverse Transcriptase. Journal of Virology, 2014, 88, 3612-3622.	1.5	116
65	The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. Current Opinion in Pharmacology, 2017, 35, 30-39.	1.7	114
66	Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210. Cancer Research, 2015, 75, 3771-3787.	0.4	112
67	Deciphering the state of immune silence in fatal COVID-19 patients. Nature Communications, 2021, 12, 1428.	5.8	107
68	Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. Journal of Leukocyte Biology, 2011, 89, 721-727.	1.5	106
69	Human fibrocytic myeloidâ€derived suppressor cells express IDO and promote tolerance via Tregâ€cell expansion. European Journal of Immunology, 2014, 44, 3307-3319.	1.6	104
70	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood, 2015, 126, 1621-1628.	0.6	104
71	Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Letters, 2008, 267, 216-225.	3.2	103
72	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget, 2016, 7, 1168-1184.	0.8	103

#	Article	IF	Citations
73	ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death and Disease, 2014, 5, e1135-e1135.	2.7	102
74	Complexity and challenges in defining myeloid-derived suppressor cells. , 2014, , n/a-n/a.		102
75	The pros and cons of chemokines in tumor immunology. Trends in Immunology, 2012, 33, 496-504.	2.9	101
76	IFN-Î³-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine, 2010, 28, 3548-3557.	1.7	98
77	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. Cancer Research, 2019, 79, 4715-4728.	0.4	97
78	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity, 2018, 48, 91-106.e6.	6.6	95
79	Fine-Needle Aspiration Molecular Analysis for the Diagnosis of Papillary Thyroid Carcinoma Through BRAFV600E Mutation and RET/PTC Rearrangement. Thyroid, 2007, 17, 1109-1115.	2.4	94
80	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. Science Immunology, 2019, 4, .	5.6	85
81	Tumor-Derived Prostaglandin E2 Promotes p50 NF-ÎºB-Dependent Differentiation of Monocytic MDSCs. Cancer Research, 2020, 80, 2874-2888.	0.4	81
82	Antigen specificity of immune suppression by myeloid-derived suppressor cells. Journal of Leukocyte Biology, 2011, 90, 31-36.	1.5	77
83	Anatomically Restricted Synergistic Antiviral Activities of Innate and Adaptive Immune Cells in the Skin. Cell Host and Microbe, 2013, 13, 155-168.	5.1	76
84	Covid-19 Interstitial Pneumonia: Histological and Immunohistochemical Features on Cryobiopsies. Respiration, 2021, 100, 488-498.	1.2	75
85	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. Cancers, 2019, 11, 1141.	1.7	71
86	Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple. Frontiers in Cell and Developmental Biology, 2020, 8, 166.	1.8	71
87	Suppressive Influences in the Immune Response to Cancer. Journal of Immunotherapy, 2009, 32, 1-11.	1.2	69
88	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 35-48.	3.3	68
89	The Endless Saga of Monocyte Diversity. Frontiers in Immunology, 2019, 10, 1786.	2.2	67
90	In Vivo Induction of Myeloid Suppressor Cells and CD4⁺Foxp3⁺T Regulatory Cells Prolongs Skin Allograft Survival in Mice. Cell Transplantation, 2011, 20, 941-954.	1.2	66

#	Article	IF	Citations
91	<i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer. Cancer Research, 2009, 69, 9376-9384.	0.4	61
92	Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biology, 2012, 13, 18.	3.0	61
93	Transcription factors in myeloid-derived suppressor cell recruitment and function. Current Opinion in Immunology, 2011, 23, 279-285.	2.4	58
94	The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment. Frontiers in Immunology, 2014, 5, 69.	2.2	58
95	Differential Control of Mincle-Dependent Cord Factor Recognition and Macrophage Responses by the Transcription Factors C/EBPÎ² and HIF1Î±. Journal of Immunology, 2014, 193, 3664-3675.	0.4	58
96	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. Cancer Research, 2019, 79, 1938-1951.	0.4	58
97	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351.	1.7	56
98	Modulation of human Tâ€cell functions by reactive nitrogen species. European Journal of Immunology, 2011, 41, 1843-1849.	1.6	54
99	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood, 2000, 96, 3838-3846.	0.6	54
100	Inhibition of Tumor-Induced Myeloid-Derived Suppressor Cell Function by a Nanoparticulated Adjuvant. Journal of Immunology, 2011, 186, 264-274.	0.4	53
101	Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Current Opinion in Immunology, 2015, 33, 120-125.	2.4	50
102	Correspondence 1: Cancer vaccines: pessimism in check. Nature Medicine, 2004, 10, 1278-1279.	15.2	49
103	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. Blood, 2019, 134, 1670-1682.	0.6	49
104	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Carcinogenesis, 2018, 39, 971-980.	1.3	48
105	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. Seminars in Immunology, 2016, 28, 54-63.	2.7	47
106	Induction of immunosuppressive functions and NF-ÎºB by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	5.8	45
107	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	1.6	44
108	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Human Pathology, 2018, 81, 157-165.	1.1	44

#	Article	IF	Citations
109	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages. Cancer Discovery, 2020, 10, 1758-1773.	7.7	44
110	Preventive Vaccination with Telomerase Controls Tumor Growth in Genetically Engineered and Carcinogen-Induced Mouse Models of Cancer. Cancer Research, 2008, 68, 9865-9874.	0.4	42
111	Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Biomatter, 2014, 4, e955386.	2.6	42
112	l-glutamine is a key parameter in the immunosuppression phenomenon. Biochemical and Biophysical Research Communications, 2012, 425, 724-729.	1.0	41
113	The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. Modern Pathology, 2021, 34, 1444-1455.	2.9	41
114	Interleukin-10 Enhances the Therapeutic Effectiveness of a Recombinant Poxvirus-Based Vaccine in an Experimental Murine Tumor Model. Journal of Immunotherapy, 1999, 22, 489-496.	1.2	40
115	Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase. Journal of Immunology, 2003, 171, 6396-6405.	0.4	39
116	Metabolic mechanisms of cancer-induced inhibition of immune responses. Seminars in Cancer Biology, 2007, 17, 309-316.	4.3	38
117	Role of microRNAs in HTLV-1 infection and transformation. Molecular Aspects of Medicine, 2010, 31, 367-382.	2.7	37
118	Leukocyte Infiltration in Cancer Creates an Unfavorable Environment for Antitumor Immune Responses: A Novel Target for Therapeutic Intervention. Immunological Investigations, 2006, 35, 327-357.	1.0	36
119	Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer and Metastasis Reviews, 2011, 30, 27-43.	2.7	36
120	High-Avidity T Cells Are Preferentially Tolerized in the Tumor Microenvironment. Cancer Research, 2013, 73, 595-604.	0.4	36
121	Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells. Journal of Controlled Release, 2019, 295, 60-73.	4.8	36
122	Protein Tyrosine Kinases and Phosphatases Control Apoptosis Induced by Extracellular Adenosine 5â€²-Triphosphate. Biochemical and Biophysical Research Communications, 1996, 218, 344-351.	1.0	35
123	Methods to Measure MDSC Immune Suppressive Activity <i>In Vitro</i> and <i>In Vivo</i>. Current Protocols in Immunology, 2019, 124, e61.	3.6	35
124	Th17 and cancer: friends or foes?. Blood, 2008, 112, 214-214.	0.6	33
125	Interferon-Î± counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis, 2009, 30, 851-860.	1.3	33
126	Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood, 2010, 115, 1374-1384.	0.6	33

#	Article	IF	Citations
127	CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells. Journal of Immunology, 2015, 195, 3482-3489.	0.4	33
128	Tumor cells hijack macrophages via lactic acid. Immunology and Cell Biology, 2014, 92, 647-649.	1.0	32
129	Arginase 1â€"Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Antiâ€"PD-1 Checkpoint Blockade. Cancer Immunology Research, 2021, 9, 1316-1326.	1.6	32
130	Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. Journal of Nanobiotechnology, 2020, 18, 31.	4.2	30
131	Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury. Oncotarget, 2015, 6, 10161-10174.	0.8	30
132	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy, 2020, 22, 474-481.	0.3	29
133	Anti-Tumor Activity of Cytotoxic T Lymphocytes Elicited with Recombinant and Synthetic Forms of a Model Tumor-Associated Antigen. Journal of Immunotherapy, 1995, 18, 139-146.	1.2	28
134	Tumor-Induced Myeloid-Derived Suppressor Cells. Microbiology Spectrum, 2016, 4, .	1.2	28
135	CD66bâ°CD64dimCD115â° cells in the human bone marrow represent neutrophil-committed progenitors. Nature Immunology, 2022, 23, 679-691.	7.0	28
136	Monocyte-Derived Suppressor Cells in Transplantation. Current Transplantation Reports, 2015, 2, 176-183.	0.9	27
137	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	3.5	27
138	Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. Scientific Reports, 2019, 9, 12286.	1.6	27
139	Complete neural stem cell (NSC) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism. Pharmacological Research, 2020, 158, 104863.	3.1	27
140	Role of Extracellular ATP in Cell-Mediated Cytotoxicity: A Study with ATP-Sensitive and ATP-Resistant Macrophages. Cellular Immunology, 1994, 156, 458-467.	1.4	26
141	Regeneration-associated WNT Signaling Is Activated in Long-term Reconstituting AC133bright Acute Myeloid Leukemia Cells. Neoplasia, 2012, 14, 1236-IN45.	2.3	26
142	Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood, 2013, 121, 1740-1748.	0.6	25
143	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. Cancer Research, 2016, 76, 2540-2551.	0.4	25
144	Differential expression of constitutive and inducible proteasome subunits in human monocyteâ€derived DC differentiated in the presence of IFNâ€<i>Î±</i> or ILâ€4. European Journal of Immunology, 2009, 39, 56-66.	1.6	24

#	Article	IF	Citations
145	4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells. Journal of Immunology, 2017, 198, 4166-4177.	0.4	23
146	Genetic Vaccination for the Active Immunotherapy of Cancer. Current Gene Therapy, 2001, 1, 53-100.	0.9	22
147	Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor Î± Usage by Melanoma-specific CD8+ T Lymphocytes. Cancer Research, 2004, 64, 8068-8076.	0.4	22
148	Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. , 2022, 10, e003549.		22
149	Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy. Science Translational Medicine, 2020, 12, .	5.8	21
150	Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells â€œ<i>in vitro</i>â€•and correlating with progression â€œ<i>in vivo</i>â€: Oncotarget, 2016, 7, 74189-74202.	0.8	21
151	Immune-Guided Therapy of COVID-19. Cancer Immunology Research, 2022, 10, 384-402.	1.6	20
152	Molecular alterations in basal cell carcinoma subtypes. Scientific Reports, 2021, 11, 13206.	1.6	19
153	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget, 2017, 8, 86987-87001.	0.8	18
154	Measurement of Myeloid Cell Immune Suppressive Activity. Current Protocols in Immunology, 2010, 91, Unit 14.17.	3.6	17
155	Tumors STING Adaptive Antitumor Immunity. Immunity, 2014, 41, 679-681.	6.6	17
156	Interfering with CCL5/CCR5 at the Tumor-Stroma Interface. Cancer Cell, 2016, 29, 437-439.	7.7	17
157	Deciphering Macrophage and Monocyte Code to Stratify Human Breast Cancer Patients. Cancer Cell, 2019, 35, 538-539.	7.7	17
158	Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b + cells that expedite hematopoietic recovery. Haematologica, 2017, 102, 818-825.	1.7	16
159	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. International Journal of Molecular Sciences, 2020, 21, 6386.	1.8	15
160	The Cross-Talk between Myeloid and Mesenchymal Stem Cells of Human Bone Marrow Represents a Biomarker of Aging That Regulates Immune Response and Bone Reabsorption. Cells, 2022, 11, 1.	1.8	15
161	Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. Xenotransplantation, 2003, 10, 587-595.	1.6	14
162	Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. Cell Death and Differentiation, 2022, 29, 420-438.	5.0	14

#	Article	IF	Citations
163	Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Frontiers in Cell and Developmental Biology, 2021, 9, 795251.	1.8	14
164	Role of anti-LFA-1 and anti-ICAM-1 combined mab treatment in the rejection of tumors induced by moloney murine sarcoma virus (M-MSV). International Journal of Cancer, 1995, 61, 355-362.	2.3	12
165	Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs). Genomics Data, 2014, 2, 389-392.	1.3	12
166	The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. Stem Cell Research and Therapy, 2021, 12, 316.	2.4	12
167	Synergistic Effect of Extracellular Adenosine 5â€²-Triphosphate and Tumor Necrosis Factor on DNA Degradation. Cellular Immunology, 1993, 152, 110-119.	1.4	11
168	Inhibition of Protein Tyrosine Phosphorylation Prevents T-Cell-Mediated Cytotoxicity. Cellular Immunology, 1994, 159, 294-305.	1.4	10
169	GM-CSF Nitration Is a New Driver of Myeloid Suppressor Cell Activity in Tumors. Frontiers in Immunology, 2021, 12, 718098.	2.2	10
170	The Transcriptional Response in Human Umbilical Vein Endothelial Cells Exposed to Insulin: A Dynamic Gene Expression Approach. PLoS ONE, 2010, 5, e14390.	1.1	8
171	Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. Clinical Lung Cancer, 2019, 20, e514-e516.	1.1	8
172	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. Frontiers in Cell and Developmental Biology, 2020, 8, 308.	1.8	8
173	The expanding constellation of immune checkpoints: a DNAMic control by CD155. Journal of Clinical Investigation, 2018, 128, 2199-2201.	3.9	8
174	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients. Frontiers in Immunology, 2021, 12, 809826.	2.2	8
175	Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. Cellular Immunology, 1989, 122, 450-460.	1.4	7
176	Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers. Cancer Discovery, 2016, 6, 821-823.	7.7	7
177	Detection and functional evaluation of arginase-1 isolated from human PMNs and murine MDSC. Methods in Enzymology, 2020, 632, 193-213.	0.4	7
178	Tolerogenic pDCs: spotlight on Foxo3. Journal of Clinical Investigation, 2011, 121, 1247-1250.	3.9	7
179	Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia. Biomedicines, 2022, 10, 1332.	1.4	7
180	Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. Cancer Immunology, Immunotherapy, 1992, 35, 27-32.	2.0	6

#	Article	IF	Citations
181	CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2?specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunology, Immunotherapy, 2004, 53, 697-704.	2.0	6
182	Smoothing T cell roads to the tumor. OncoImmunology, 2012, 1, 390-392.	2.1	6
183	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation. , 2013, , 597-634.		6
184	Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data. European Journal of Cancer, 2021, 148, 348-358.	1.3	6
185	Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Journal of Immunology Research, 2022, 2022, 1-21.	0.9	6
186	Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. Journal of Biotechnology, 2011, 152, 43-48.	1.9	5
187	Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. Immunology, 2015, 146, 33-49.	2.0	5
188	Fhit down-regulation is an early event in pancreatic carcinogenesis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 647-653.	1.4	5
189	Peripheral blood immunophenotyping in a large cohort of patients with Shwachmanâ€“Diamond syndrome. Pediatric Blood and Cancer, 2019, 66, e27597.	0.8	5
190	Macrophages Instruct Aberrant Glycosylation in Colon Cancer by Chemokine and Cytokine Signals. Cancer Immunology Research, 2020, 8, 160-160.	1.6	5
191	Nitric oxide affects immune cells bioenergetics. Immunobiology, 2012, 217, 808-815.	0.8	4
192	Transgenic mice overexpressing arginase 1 in monocytic cell lineage are affected by lymphoâ€“myeloproliferative disorders and disseminated intravascular coagulation. Carcinogenesis, 2015, 36, 1354-1362.	1.3	3
193	Wntâ€“Î²-catenin as an epigenetic switcher in colonic Treg cells. Nature Immunology, 2021, 22, 400-401.	7.0	3
194	Myeloid-Derived Suppressor Cells in Cancer. , 2008, , 157-195.		3
195	Cancer rejection by the immune system: Forcing the check-points of tumor immune escape. Drug Discovery Today Disease Mechanisms, 2005, 2, 191-197.	0.8	2
196	Generation of Pancreatic Organoid-Derived Isografts. STAR Protocols, 2020, 1, 100047.	0.5	2
197	How to Reprogram Myeloma-Associated Macrophages: Target IKZF1. Cancer Immunology Research, 2021, 9, 254-254.	1.6	2
198	Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance. , 2014, , 99-150.		2

#	Article	IF	Citations
199	Molecular genetics of cancer. Gene therapy and other novel therapeutic approaches. Cancer, 1995, 76, 1878-1881.	2.0	1
200	From Oncogene Interference to Neutrophil Immune Modulation. Immunity, 2017, 47, 613-615.	6.6	1
201	The mesenchymal and myeloid regulation of immunity: Power is nothing without control. Seminars in Immunology, 2018, 35, 1-2.	2.7	1
202	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. Pathology Research and Practice, 2018, 214, 1675-1680.	1.0	1
203	Increased Arginase1 expression in tumor microenvironment promotes mammary carcinogenesis via multiple mechanisms. Carcinogenesis, 2020, 41, 1695-1702.	1.3	1
204	Tumor-Induced Myeloid-Derived Suppressor Cells. , 0, , 833-856.		1
205	Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches. Advances in Delivery Science and Technology, 2014, , 187-214.	0.4	1
206	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation. , 2007, , 369-399.		0
207	Tumour-Induced Immune Suppression by Myeloid Cells. , 2011, , 49-62.		0
208	Close to the Bone: Tissue-Specific Checkpoint Immunotherapy Evasion. Cell, 2019, 179, 1010-1012.	13.5	0
209	Oncolytic virotherapy meets the human organoid technology for pancreatic cancers. EBioMedicine, 2020, 57, 102828.	2.7	0
210	Galectin-1 Supports a Dangerous Liaison between Monocytes and Multiple Myeloma. Cancer Immunology Research, 2021, 9, 488-488.	1.6	0
211	Abstract 302: Multiple distinct populations of myeloid derived suppressor cells in IMA901 treated renal cell cancer patients correlate with survival and with T-cell dysfunctions. , 2011, , .		0
212	Abstract 473: CD4+ T cell help differentially influences anti-tumor immunity as a function of T cell avidity. , 2011, , .		0
213	Myeloid-Derived Suppressor Cells in Cancer. , 2012, , 217-229.		0
214	Abstract 5365: Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide. , 2012, , .		0
215	Abstract 1449:In vivotargeted silencing of CCR1 and CCR5 repolarizes pro-tumoral myeloid cells in retinoblastoma positive neutrophils with a strong anti-tumor activity. , 2016, , .		0
216	Abstract IA13: Immune suppressive and immune stimulating monocytes in cancer. , 2016, , .		0

#	Article	IF	Citations
217	Phenotypical Characterization and Isolation of Tumor-Derived Mouse Myeloid-Derived Suppressor Cells. Methods in Molecular Biology, 2021, 2236, 29-42.	0.4	0
218	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15â€“16, 2020. Cancer Immunology, Immunotherapy, 2022, , 1.	2.0	0
219	Ursula Grohmann, PhD: In Memoriam (1961â€“2022). Cancer Immunology Research, 0, , OF1-OF1.	1.6	0